RNA-based drugs depend on chemical modifications to increase potency and nuclease sta-1 bility, and to decrease immunogenicity in vivo. Chemical modification will likely improve 2 the guide RNAs involved in CRISPR-Cas9-based therapeutics as well. Cas9 orthologs are 3 RNA-guided microbial effectors that cleave DNA. No studies have yet explored chemical 4 modification at all positions of the crRNA guide and tracrRNA cofactor. Here, we have iden-5 tified several heavily-modified versions of crRNA and tracrRNA that are more potent than 6 their unmodified counterparts. In addition, we describe fully chemically modified crRNAs 7 and tracrRNAs (containing no 2'-OH groups) that are functional in human cells. These de-8 signs demonstrate a significant breakthrough for Cas9-based therapeutics since heavily 9 modified RNAs tend to be more stable in vivo (thus increasing potency). We anticipate that 10 our designs will improve the use of Cas9 via RNP and mRNA delivery for in vivo and ex vivo 11 purposes.
crRNA contains a guide sequence that directs the Cas9 RNP to a specific locus via base-pairing with the 20 target DNA to form an R-loop. This process requires the prior recognition of a protospacer adjacent motif 21 (PAM), which for SpyCas9 is NGG. R-loop formation activates the His-Asn-His (HNH) and RuvC-like 22 endonuclease domains that cleave the target strand and the non-target strand of the DNA, respectively, 23 resulting in a double-strand break (DSB).
24
For mammalian applications, Cas9 and its guide RNAs can be expressed from DNA (e.g. a viral vector),
25
RNA (e.g. Cas9 mRNA plus guide RNAs in a lipid nanoparticle), or introduced as an RNP. Viral delivery 26 of Cas9 results in efficient editing, but can be problematic because long-term expression of Cas9 and its 27 guides can result in off-target editing, and viral vectors can elicit strong host immune responses. 5 RNA and 28 RNP delivery platforms of Cas9 are suitable alternatives to viral vectors for many applications and have 29 recently been shown to be effective genome editing tools in vivo. 6,7 RNP delivery of Cas9 also bypasses the 30 requirement for Cas9 expression, leading to faster editing. Furthermore, Cas9 delivered as mRNA or RNP 31 exists only transiently in cells and therefore exhibits reduced off-target editing. For instance, Cas9 RNPs 32 were successfully used to correct hypertrophic cardiomyopathy (HCM) in human embryos without measur-33 able off-target effects. 8
34
The versatility of Cas9 for genome editing derives from its RNA-guided nature. The crRNA of SpyCas9 35 used in this study consists of a 20-nt guide region followed by a 16-nt repeat region ( Figure 1A) . The tra-36 crRNA consists of an anti-repeat region that pairs with the crRNA, and also includes three stem-loops. All 37 of these secondary structure elements are required for efficient editing in mammalian systems. 9 However,
38
unmodified RNAs are subject to rapid degradation in circulation and within cells. 10,11 Therefore, it is highly 39 desirable to chemically protect RNAs for efficient genomic editing in hard-to-transfect cells and in vivo. Thus,
40
it has been previously reported that chemical modifications in the crRNA and tracrRNA enhance stability 41 and editing efficiency in vivo and ex vivo . 6,7,11-13 Chemical modifications including 2'-O-methyl (2'-OMe), 42 phosphorothioate (PS), 2'-O-methyl thioPACE (MSP), 2'-fluoro RNA (2'-F-RNA) and constrained ethyl (S-43 cEt) have previously been employed to synthesize crRNA and tracrRNA. 6, 11, 12 The modified RNAs not only 44 improved Cas9 efficacy, but in some instances also improved specificity. 11, 14 Modifications were either based 45 on the crystal structures of Cas9 or limited to the ends of RNAs, and the guides were not modified exten-46 sively. Nonetheless, heavily or fully modified RNAs may have advantages in vivo. 10 Modified siRNAs and 47 ASOs substantially improve stability and potency, and can also reduce off-target effects. Furthermore, ex-48 tensively modified RNAs can prevent innate immune responses. 15
49
In the present study, we sought to extensively modify the crRNA and tracrRNA while retaining the efficacy 50 of SpyCas9-based genome editing in cultured human cells. We used structure-guided and systematic ap-51 proaches to introduce 2'-OMe-RNA, 2'-F-RNA and PS modifications ( Figure 1B ) throughout guide RNAs 52 (Table S1 ). Our strategy yielded active RNP complexes with both extensively and fully modified versions of 53 crRNAs and tracrRNAs.
54
Crystal structures of SpyCas9 have been solved as the RNP alone or bound to one or both strands of 55 target DNA. [16] [17] [18] [19] These structures provide detailed information regarding the interactions between the Cas9 56 protein and crRNA:tracrRNA complex. We used these structures to identify sites where Cas9 protein makes 57 no contacts with the crRNA or tracrRNA. Thus, in our initial screen, 2'-OMe modifications were intro-58 duced at guide positions 7-10 and 20 (C2, Figure 1C ). Similarly, positions 21 and 27-36 in the crRNA repeat 59 region were also modified using 2'-OMe. To improve nuclease stability, PS modifications were also intro-60 duced at the 5' end of the crRNA, yielding the C3 design ( Figure 1C and Table 1 ). In parallel, we tested a 61 crRNA that was more aggressively modified to leave only nine nucleotides (nt) unprotected (C1). Similarly, 62 2'-OMe modifications were also introduced into the tracrRNA at all positions where no protein contact with 63 the RNA is observed. This gave rise to T1 that is 50% chemically modified ( Figure 2 and Table 2 ). 
64

67
The crRNAs and tracrRNAs were tested in a HEK293T cell line stably expressing the traffic light reporter 
71
ogous end-joining DSB repair events. 20 As shown in Figure 1C , modified crRNAs 2 and 3 retain complete 72 activity relative to the unmodified crRNA C0, suggesting that the modifications introduced in crRNAs 2 73 and 3 are well tolerated by Cas9. Lipid-based delivery of Cas9 RNP complex showed that C3 was even 74 more efficacious than C0 and C2 ( Figure S1 ), which demonstrates the importance of PS linkages at the 5' 75 terminus of the crRNA. Similarly, T1 did not hinder Cas9 activity. On the other hand, the extra modifica-76 tions introduced in C1 almost completely abolished Cas9 activity in cells. We reasoned that the 2'-OMe 77 modifications (especially at positions 16-18 in the crRNA) are most likely to compromise Cas9 RNP activity 78 since nt at position 16 and 18 were shown to make base-specific contacts with Arg447 and Arg71. 16 The 2'-
79
OH of G16 in the TLR crRNA is also predicted to make a hydrogen bond with Arg447. We chose C3 and 80 T1 as a basis for further optimization.
81
In the second round of crRNA modification, we introduced additional 2'-OMe modifications into the We also incorporated 2'-F-RNAs in this round of optimization since they can increase thermal and nu-99 clease stability of RNA:RNA or RNA:DNA duplexes, and they also interfere minimally with C3'-endo sugar 100 puckering. 21,22 2'-F may be better tolerated than 2'-OMe at positions where the 2'-OH is important for 101 RNA:DNA duplex stability. For these reasons, we synthesized two crRNAs based on C9 but with 2'-F mod- 
108
C10 has great potential to provide increased stability, and therefore more efficient editing, in vivo. 
109
111
We also carried out a second round of tracrRNA optimization. T1 was further modified by introducing 112 2'-OMe substitutions at most positions where the 2'-OH groups do not make crystal contacts with the pro-113 tein. In addition, some nts that interact with Cas9 were also modified, given that the crRNA tolerated sub- 
123
The mCherry signal only results from indels producing a +1 frameshift, and therefore underestimates true 124 editing efficiencies. To ensure that crRNA:tracrRNA combinations do not yield false negatives by favoring
125
TLR indels that are out of the mCherry reading frame, we also carried out Tracking of Indels by Decom-126 position (TIDE) analysis to analyze overall editing efficiencies. As shown in Figure S2 , editing efficiencies 127 measured using TIDE correlate well with the mCherry signal.
128
When C17-C22 were used with either T2 or the T0 control (20 pmol RNP), all showed comparable 151 efficacy as the C0 and C10 crRNAs ( Figure 3B ). This includes the fully modified C21 that is either 2'-F-or 152 2'-OMe-substituted at every position. To our knowledge, this is the first time a completely modified and 153 fully functional crRNA has been reported. C21 loses some efficacy when combined with T6-T8, and is also 154 less potent than C0 when lower (3 pmole) doses of RNP are delivered ( Figure S4 ). These losses may be due 155 to compromised base pairing between the heavily modified repeat:anti-repeat duplexes. Across all tracrR-
156
NAs tested, C20 exhibits the highest editing efficiency. In addition, at 3 pmol RNP, C20 is more potent 157 than unmodified C0, suggesting enhanced stability in cells ( Figure S4 ). Although C20 includes six ribose 158 sugars, each is adjacent to a PS modification, leaving no unmodified linkages in the crRNA.
159
Among T6-T8, the best-performing tracrRNA was T6, especially with modified crRNAs including C20.
160
The fully-modified tracrRNA (T8) compromised the potency of all crRNAs tested, but retains some func-161 tion (~5% editing with 20 pmol RNP) with C19 and C20 ( Figure 3B ). To test whether the T8 activity 162 improves at higher doses, we nucleofected cells with 100 pmol Cas9 RNP. We found that by using a higher 163 amount of Cas9 RNP, the editing efficiency of T8 in combination with C0 or C20 is rescued to the same 164 level as observed using 20 pmol of Cas9 RNP with C0:T0 (Figure 3 ). Furthermore, at higher doses, the 165 efficacy of C20:T8 is almost as high as that of C20:T0. Lastly, the editing efficiency of the fully-modified 
168
While the editing efficiency is not as high as that of the unmodified RNAs in cells, the increased serum stability afforded by the fully chemically optimized C21:T8 combination ( Figure S5 ) would likely provide 170 significant benefits in vivo, as observed for fully modified siRNAs and ASOs.
171
To verify that our crRNA designs are compatible with different guide sequences, including those targeting 172 endogenous human genes, we tested the C10, C20 and C21 designs targeting the huntingtin (HTT), human 
184
C10 and C20 may be more efficacious (but never less efficacious) than the unmodified crRNA, similar to 185 what was observed in Figure S4 , but this effect seemed to vary between target sites ( Figure S8 ). C20 also 186 showed higher potency compared to C0 when tested in human embryonic stem cells (hESC) ( Figure 4E ).
187
In hESC the highest potency was achieved using the heavily modified combination C20:T2. Furthermore,
188
the fully modified crRNA C21 was just as efficacious as the minimally modified C0. We also examined 189 editing in HEK293T cells at the top off-target site for both HBB and VEGFA, as validated previously. 14,23
190
The modified crRNAs do not significantly affect off-target editing, though the fully modified C21:T8 may 191 provide slight specificity improvements compared to the less heavily modified designs ( Figure S9 ). Collec-
192
tively these results demonstrate that our modified crRNA designs can be applied to endogenous target sites. (Table S1 ). All of the modified RNAs 202 outperformed in vitro-transcribed sgRNA as well as synthetic, unmodified dual RNAs ( Figure S6 ). Further-203 more, at lower concentrations, hiGC-C1 exhibit increased potency relative to non-optimized versions of 204 unmodified or modified RNAs ( Figure S6 ). However, this trend does not hold true in HTT-hiGC C1 (Figure   205 S6). Therefore, these mutant sequences may be superior to wild-type sequences in a guide-sequence-specific 206 manner.
207
In summary, we used a structure-guided approach combined with systematic addition of modifications to 208 identify heavily-or fully-modified crRNAs and tracrRNAs that direct SpyCas9 genome editing in human 209 cells. Two pairs of crRNA:tracrRNA stand out as particularly promising. First, C20:T2 is our most potent 210 combination, and both RNAs contain ribose substitutions at >80% of their nts. Furthermore, C20 contains 211 at least one chemical modification (2'-OMe, 2'-F or PS) at every single position. The C20:T2 combination 212 is more potent than its unmodified crRNA:tracrRNA counterpart when tested in human cells. Second,
213
although the C21:T8 combination exhibits reduced potency in human cells, its significant functionality is 214 still noteworthy because it is completely devoid of ribose sugars. This will greatly ease chemical synthesis, 
